Glioblastoma are among the most vascularized of all solid tumors and attractive targets for antiangiogenic therapies. Antiangiogenic therapy response assessment in glioblastoma is challenging due to decreased vessel permeability and diminished contrast agent extravasation. Here, we investigated the variability of vascular hysteresis loop (VHL) shapes and the spatial heterogeneity of neovascularization using vascular architecture mapping (VAM) in patients with recurrent glioblastoma during bevacizumab mono-therapy. Responding, non-responding, progressive, and remote-progressive tumor areas were observed. Analysis of VHLs in combination with VAM biomarkers may lead to a new perspective on investigating the spatial heterogeneity of neovascularization in glioblastoma during antiangiogenic therapy.